help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BHALLA, K. S.
Right arrow Articles by FOLZ, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BHALLA, K. S.
Right arrow Articles by FOLZ, R. J.

Am. J. Respir. Crit. Care Med., Volume 161, Number 1, January 2000, 17-25

Pulmonary Toxicity of Induction Chemotherapy Prior to Standard or High-dose Chemotherapy with Autologous Hematopoietic Support

KARAN S. BHALLA, STEPHEN W. WILCZYNSKI, AMIR M. ABUSHAMAA, WILLIAM P. PETROS, CAROLYN S. MCDONALD, JENNIFER S. LOFTIS, NELSON J. CHAO, JAMES J. VREDENBURGH, and RODNEY J. FOLZ

Duke University Medical Center, Departments of Medicine and Cell Biology, Divisions of Pulmonary and Critical Care Medicine and Hematology/Oncology, Durham, North Carolina

We closely followed the pulmonary function of 150 consecutive high-risk breast cancer patients who underwent standard induction CAF (cyclophosphamide, doxorubicin, 5-fluorouracil) chemotherapy, followed by randomization to either standard-dose CPB (cyclophosphamide, cisplatin, bischloroethylnitrosourea [BCNU]) chemotherapy (SDC) or to high-dose CPB chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) and peripheral blood progenitor cell support (PBPCS). Previously, we have described a delayed pulmonary toxicity syndrome (DPTS) which characterizes the pulmonary dysfunction after HDC and ABMT in this patient population. However, little is known concerning the role induction chemotherapy plays in its development. We found that after three cycles of induction CAF, the mean diffusing capacity of the lungs for carbon monoxide (DLCO) significantly decreased by 12.6%. Additionally, in patients receiving HDC, the mean DLCO further decreased to a nadir of 55.2 ± 14.1% which was significantly lower than those receiving SDC (nadir: 80.7 ± 12.3%). DPTS occurred in 72% of patients receiving HDC as compared with only 4% of patients receiving SDC. All individuals diagnosed with DPTS were treated with prednisone and the 2-yr follow-up of pulmonary function revealed a gradual improvement in mean DLCO such that there were no differences between HDC and SDC groups at the end of the study. No mortality was attributable to pulmonary toxicity in either group. After induction chemotherapy, but before HDC, bronchoalveolar lavage (BAL) demonstrated significant elevations in interleukin-6 (IL-6), IL-8, neutrophils, and lymphocytes. We conclude that induction CAF produces asymptomatic pulmonary dysfunction and inflammation which may prime the lungs for further injury by HDC and predispose to the development of DPTS. Fortunately, in this specific ABMT patient population, the early and judicious use of prednisone appears to improve pulmonary function in patients who develop DPTS. Bhalla KS, Wilczynski SW, Abushamaa AM, Petros WP, McDonald CS, Loftis JS, Chao NJ, Vredenburgh JJ, Folz RJ. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.




This article has been cited by other articles:


Home page
 Ann OncolHome page
R. Yerushalmi, M. R. Kramer, S. Rizel, A. Sulkes, K. Gelmon, T. Granot, V. Neiman, and S. M. Stemmer
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
Ann. Onc., March 1, 2009; 20(3): 437 - 440.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. Tichelli, A. Rovo, and A. Gratwohl
Late Pulmonary, Cardiovascular, and Renal Complications after Hematopoietic Stem Cell Transplantation and Recommended Screening Practices
Hematology, January 1, 2008; 2008(1): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S.-i. Takeda, Y. Funakoshi, Y. Kadota, M. Koma, H. Maeda, S. Kawamura, and Y. Matsubara
Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?
Ann. Thorac. Surg., July 1, 2006; 82(1): 232 - 236.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. E. Traynor, T. C. Corbridge, A. E. Eagan, W. G. Barr, Q. Liu, Y. Oyama, and R. K. Burt
Prevalence and Reversibility of Pulmonary Dysfunction in Refractory Systemic Lupus: Improvement Correlates With Disease Remission Following Hematopoietic Stem Cell Transplantation
Chest, May 1, 2005; 127(5): 1680 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Milla, S. Yang, D. N. Cornfield, M.-L. Brennan, S. L. Hazen, A. Panoskaltsis-Mortari, B. R. Blazar, and I. Y. Haddad
Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation
Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L706 - L714.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Kotloff, V. N. Ahya, and S. W. Crawford
Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. A. Qureshi, R. E. Girgis, H. K. Dandapantula, J. Abrams, and A. O. Soubani
Increased Exhaled Nitric Oxide Following Autologous Peripheral Hematopoietic Stem-Cell Transplantation: A Potential Marker of Idiopathic Pneumonia Syndrome
Chest, January 1, 2004; 125(1): 281 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
I. Y. Haddad
Idiopathic Pneumonia after Marrow Transplantation: When Are Antioxidants Effective?
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1532 - 1534.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. S. Bhalla and R. J. Folz
Idiopathic Pneumonia Syndrome after Syngeneic Bone Marrow Transplant in Mice
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1579 - 1589.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
Ph. Camus, P. Foucher, Ph. Bonniaud, and K. Ask
Drug-induced infiltrative lung disease
Eur. Respir. J., July 1, 2001; 18(32_suppl): 93S - 100s.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
J. R. Wright, P. Borron, K. G. Brinker, and R. J. Folz
Surfactant Protein A . Regulation of Innate and Adaptive Immune Responses in Lung Inflammation
Am. J. Respir. Cell Mol. Biol., May 1, 2001; 24(5): 513 - 517.
[Full Text]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Wu, M. R. Kelley, W. K. Hansen, and W. J. Martin II
Reduction of BCNU toxicity to lung cells by high-level expression of O6-methylguanine-DNA methyltransferase
Am J Physiol Lung Cell Mol Physiol, April 1, 2001; 280(4): L755 - L761.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Briasoulis and N. Pavlidis
Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy
Oncologist, April 1, 2001; 6(2): 153 - 161.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS 2008 State of the Art Course